Evidence map›Paper›PMID 38491408›Full record

ArticleBiology of sex differences2024

Integrative multi-omics characterization reveals sex differences in glioblastoma.

Byunghyun Jang, Dayoung Yoon, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Harim Koo, Jason K Sa

Abstract read
In one paragraph

Article in Biology of sex differences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Multi-Omics Integration for Advancing Glioma Precision Medicine.Annals of clinical and translational neurology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Byunghyun JangDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Dayoung YoonDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Ji Yoon LeeDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Jiwon KimDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Jisoo HongDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Harim KooDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
Jason K SaDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea. jasonksa@korea.ac.kr.ORCID 0000-0002-3251-5004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with limited treatment modalities and poor prognosis. Recent studies have highlighted the importance of considering sex differences in cancer incidence, prognosis, molecular disparities, and treatment outcomes across various tumor types, including colorectal adenocarcinoma, lung adenocarcinoma, and GBM.

methodsWe performed comprehensive analyses of large-scale multi-omics data (genomic, transcriptomic, and proteomic data) from TCGA, GLASS, and CPTAC to investigate the genetic and molecular determinants that contribute to the unique clinical properties of male and female GBM patients.

resultsOur results revealed several key differences, including enrichments of MGMT promoter methylation, which correlated with increased overall and post-recurrence survival and improved response to chemotherapy in female patients. Moreover, female GBM exhibited a higher degree of genomic instability, including aneuploidy and tumor mutational burden. Integrative proteomic and phosphor-proteomic characterization uncovered sex-specific protein abundance and phosphorylation activities, including EGFR activation in males and SPP1 hyperphosphorylation in female patients. Lastly, the identified sex-specific biomarkers demonstrated prognostic significance, suggesting their potential as therapeutic targets.

conclusionsCollectively, our study provides unprecedented insights into the fundamental modulators of tumor progression and clinical outcomes between male and female GBM patients and facilitates sex-specific treatment interventions. Highlights Female GBM patients were characterized by increased MGMT promoter methylation and favorable clinical outcomes compared to male patients. Female GBMs exhibited higher levels of genomic instability, including aneuploidy and TMB. Each sex-specific GBM is characterized by unique pathway dysregulations and molecular subtypes. EGFR activation is prevalent in male patients, while female patients are marked by SPP1 hyperphosphorylation.

Indexed as

Brain NeoplasmsGlioblastomaAdultAneuploidyErbB ReceptorsFemaleGenomic InstabilityHumansMaleMultiomicsProteomicsSex CharacteristicsErbB ReceptorsGlioblastomaMulti-omicsProteomicsSex-difference

Identifiers

PMID38491408
PMCPMC10943869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.